An Evaluation of Kinerase Pro+Therapy Regimen Vs. Kinerase Vs. Control for the Treatment of Skin Aging

This study has been terminated.
Sponsor:
Information provided by:
Innovative Medical
ClinicalTrials.gov Identifier:
NCT00492479
First received: June 25, 2007
Last updated: December 18, 2007
Last verified: December 2007
  Purpose

The purpose of this study is to compare the efficacy of the Kinerase Pro+Therapy regimen versus a single Kinerase product vs. control for the treatment of the signs of skin aging.


Condition Intervention Phase
Skin Aging
Drug: Kinerase Pro+Therapy Line day repair, serum, night repair
Drug: Kinerase Pro+Therapy Line Ultra rich day repair
Drug: LubriDerm
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind

Resource links provided by NLM:


Further study details as provided by Innovative Medical:

Study Start Date: June 2007
Study Completion Date: December 2007
  Eligibility

Ages Eligible for Study:   35 Years to 55 Years
Genders Eligible for Study:   Female
Criteria

Inclusion Criteria:

  • Female patients 35-55 years of age with at least moderate signs of facial aging
  • Written informed consent
  • Likely to complete all study visits and follow study protocol

Exclusion Criteria:

  • Any dermatological or medical condition which would make patient participation unsafe or interfere with study outcomes or measurements
  • Known hypersensitivity to any study product or their components
  • Recent (within 4 weeks of baseline) surgical treatment to face (including IPL and other laser procedures)
  • Prior use of anti-aging treatments for 30 days prior to study entry (physician dispensed or prescribed treatments)
  • Planned facial procedures during the study (microdermabrasion, facials, etc)

    o Botox and fillers cannot be used during the trial or for 3 months prior to study entry

  • Recent (within 60 days) or concurrent participation in another clinical trial
  • Concomitant topical or systemic therapy that my interfere with study measurements or outcomes
  • Use of any other topical photoaging/antiaging therapies during the study, other than the prescribed study regimens
  • Patients who are habitual tanners (outdoors or with tanning beds) who plan on tanning during the study
  • Wearing of cosmetics during study visits
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00492479

Locations
United States, California
Steve Yoelin MD practice
Santa Ana, California, United States, 92701
Sponsors and Collaborators
Innovative Medical
Investigators
Principal Investigator: Steven Yoelin, MD Private Practice
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00492479     History of Changes
Other Study ID Numbers: 5314
Study First Received: June 25, 2007
Last Updated: December 18, 2007
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Kinetin
Plant Growth Regulators
Growth Substances
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on April 17, 2014